Autoimmune disease
A series of five Reviews specially commissioned by Nature Immunology discuss the genetic, environmental, microbial, and cellular factors underpinning autoimmune disease as well as cover promising avenues for therapeutic intervention.
Produced with support from Janssen Research & Development
This Focus is editorially independent, produced with financial support from a third party. About this content.
Nature Immunology is pleased to acknowledge the financial support of Janssen Research & Development in producing this Focus on Autoimmune disease. The sponsor retains sole responsibility for the following message.
Janssen Immunology is a place where passion meets purpose. Our ultimate vision is a world free from immune diseases and we recognize that, to achieve this, we must understand science to deliver therapies that treat, prevent, intercept and cure immune-mediated diseases.
Our employees are committed to harnessing all knowledge and resources available to influence the power of science and better the lives of people throughout the world. With research being conducted across the globe, we consider ourselves as leaders and innovators in the immune disease space. For more than 20 years, we have worked tirelessly to change the treatment paradigm for patients and their families.
The Janssen Immunology portfolio is seemingly unmatched. Including life-changing therapies such as REMICADE® (infliximab), SIMPONI® (golimumab), SIMPONI ARIA® (golimumab), STELARA® (ustekinumab) and TREMFYA® (guselkumab), we continue to gain approvals for new indications and in new countries while extending our influence in immunology.
Together, we look to become champions of science by treating, intercepting and curing immune diseases once and for all.
For more information about Janssen Immunology, please visit www.janssen.com/immunology.
